Objetives. To determine the correlation between prolactin levels and disease activity classified based on the Mexican lupus erythematosus disease systemic activity index (MEX SLEDAI). Methods. In this cross-sectional observational study, serum prolactin, age, sex, treatment, as well as manifestations of active disease were determined. Disease activity was evaluated using the Mexican Systemic Lupus Erythematosus Activity Index (MEX-SLEDAI). The correlation of MEX-SLEDAI with prolactin was determined using the Spearman correlation coefficient. The significance of differences between continuous variables was determined with the non-paired Student’s t test and the significance of differences between categorical variables was determined with Chi-square test. Results. 55 patients were included, 10 (18.1%) had MEX-SLEDAI ≥7 and 45 (81.8%) less than 7. A positive correlation was found with a Spearman rho 0.387 (p = 0.004) between the MEX-SLEDAI and the levels serum prolactin. Subjects with active disease and hyperprolactinemia had 80% manifestations at the renal level (p = 0.001). Conclusion. There is significant correlation between prolactin levels and disease activity. Hyperprolactinemia were detected in patients with renal activity as well as those with MEX-SLEDAI ≥7.
| Published in | International Journal of Biomedical Engineering and Clinical Science (Volume 7, Issue 4) |
| DOI | 10.11648/j.ijbecs.20210704.11 |
| Page(s) | 73-76 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Systemic Lupus Erythematosus, MEX-SLEDAI, Prolactin
| [1] | Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. Elsevier Health Sciences; 2018. 1808 p. |
| [2] | McMurray RW, May W. Sex hormones and systemic lupus erythematosus: Review and meta-analysis. Arthritis Rheum. 2003; 48 (8): 2100–10. |
| [3] | Cárdenas-Mondragón G, Ulloa-Aguirre A, Isordia-Salas I, Goffin V, Leaños-Miranda A. Elevated Serum Bioactive Prolactin Concentrations in Patients with Systemic Lupus Erythematosus Are Associated with Disease Activity as Disclosed by Homologous Receptor Bioassays. J Rheumatol. 2007; 34 (7): 1514–21. |
| [4] | Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and autoimmunity. Front Immunol. 2018; 9 (FEB): 1–8. |
| [5] | Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus. 2001; 10 (8): 554–61. |
| [6] | Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol. 1992; 19 (10): 1551–8. |
| [7] | Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J. Prolactin in human systemic lupus erythematosus. Lupus. 2001; 10 (10): 748–56. |
| [8] | Vera-Lastra O, Mendez C, Jara LJ, Cisneros M, Medina G, Ariza R, et al. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol. 2003; 30 (10): 2140–6. |
| [9] | Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity. Am J Med Sci. 1992; 303 (4): 222–6. |
| [10] | Asyraf, WA Wan, et al. "The association between serum prolactin levels and interleukin-6 and systemic lupus erythematosus activity." Reumatismo 70. 4 (2018): 241-250. |
| [11] | Walker SE, Yu-Lee LY. Overview: Prolactin and autoimmunity. Lupus. 2001; 10 (10): 659. |
| [12] | Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Torres-Aguilar H, Navarro C, et al. Prolactin has a pathogenic role in systemic lupus erythematosus. Immunol Res. 2017; 65 (2): 512–23. |
| [13] | Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, Di Carlo R. Elevated bioactive prolactin levels in systemic lupus erythematosus - Association with disease activity. J Rheumatol. 2001; 28 (10): 2216–21. |
APA Style
Jorge Medina Castillo, María Azucena Ramos Sánchez, Ariana Maia Becerra Márquez. (2021). Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus. International Journal of Biomedical Engineering and Clinical Science, 7(4), 73-76. https://doi.org/10.11648/j.ijbecs.20210704.11
ACS Style
Jorge Medina Castillo; María Azucena Ramos Sánchez; Ariana Maia Becerra Márquez. Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus. Int. J. Biomed. Eng. Clin. Sci. 2021, 7(4), 73-76. doi: 10.11648/j.ijbecs.20210704.11
AMA Style
Jorge Medina Castillo, María Azucena Ramos Sánchez, Ariana Maia Becerra Márquez. Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus. Int J Biomed Eng Clin Sci. 2021;7(4):73-76. doi: 10.11648/j.ijbecs.20210704.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijbecs.20210704.11,
author = {Jorge Medina Castillo and María Azucena Ramos Sánchez and Ariana Maia Becerra Márquez},
title = {Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus},
journal = {International Journal of Biomedical Engineering and Clinical Science},
volume = {7},
number = {4},
pages = {73-76},
doi = {10.11648/j.ijbecs.20210704.11},
url = {https://doi.org/10.11648/j.ijbecs.20210704.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbecs.20210704.11},
abstract = {Objetives. To determine the correlation between prolactin levels and disease activity classified based on the Mexican lupus erythematosus disease systemic activity index (MEX SLEDAI). Methods. In this cross-sectional observational study, serum prolactin, age, sex, treatment, as well as manifestations of active disease were determined. Disease activity was evaluated using the Mexican Systemic Lupus Erythematosus Activity Index (MEX-SLEDAI). The correlation of MEX-SLEDAI with prolactin was determined using the Spearman correlation coefficient. The significance of differences between continuous variables was determined with the non-paired Student’s t test and the significance of differences between categorical variables was determined with Chi-square test. Results. 55 patients were included, 10 (18.1%) had MEX-SLEDAI ≥7 and 45 (81.8%) less than 7. A positive correlation was found with a Spearman rho 0.387 (p = 0.004) between the MEX-SLEDAI and the levels serum prolactin. Subjects with active disease and hyperprolactinemia had 80% manifestations at the renal level (p = 0.001). Conclusion. There is significant correlation between prolactin levels and disease activity. Hyperprolactinemia were detected in patients with renal activity as well as those with MEX-SLEDAI ≥7.},
year = {2021}
}
TY - JOUR T1 - Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus AU - Jorge Medina Castillo AU - María Azucena Ramos Sánchez AU - Ariana Maia Becerra Márquez Y1 - 2021/11/19 PY - 2021 N1 - https://doi.org/10.11648/j.ijbecs.20210704.11 DO - 10.11648/j.ijbecs.20210704.11 T2 - International Journal of Biomedical Engineering and Clinical Science JF - International Journal of Biomedical Engineering and Clinical Science JO - International Journal of Biomedical Engineering and Clinical Science SP - 73 EP - 76 PB - Science Publishing Group SN - 2472-1301 UR - https://doi.org/10.11648/j.ijbecs.20210704.11 AB - Objetives. To determine the correlation between prolactin levels and disease activity classified based on the Mexican lupus erythematosus disease systemic activity index (MEX SLEDAI). Methods. In this cross-sectional observational study, serum prolactin, age, sex, treatment, as well as manifestations of active disease were determined. Disease activity was evaluated using the Mexican Systemic Lupus Erythematosus Activity Index (MEX-SLEDAI). The correlation of MEX-SLEDAI with prolactin was determined using the Spearman correlation coefficient. The significance of differences between continuous variables was determined with the non-paired Student’s t test and the significance of differences between categorical variables was determined with Chi-square test. Results. 55 patients were included, 10 (18.1%) had MEX-SLEDAI ≥7 and 45 (81.8%) less than 7. A positive correlation was found with a Spearman rho 0.387 (p = 0.004) between the MEX-SLEDAI and the levels serum prolactin. Subjects with active disease and hyperprolactinemia had 80% manifestations at the renal level (p = 0.001). Conclusion. There is significant correlation between prolactin levels and disease activity. Hyperprolactinemia were detected in patients with renal activity as well as those with MEX-SLEDAI ≥7. VL - 7 IS - 4 ER -
Information
Email: